test

Developmental Therapeutics

Joseph Paul Eder MD

Professor of Medicine (Medical Oncology)

Clinical Interests

Some particular areas of past and present involvement in the development of novel therapeutics include high dose chemotherapy, the modulation/ reversal of drug resistance, growth factors, vaccines, signal transduction pathway inhibitors, cell cycle inhibitors, and the therapeutic use of antiangiogenisis agents. In this area, I have interest in developing pharmacodynamic markers of antiangiogenic effects in the clinic including MRI and PET imaging, circulating endothelial cells, monitoring interstitial fluid pressures and the evaluation of tumor biopsies after therapy. The clinical role of pathways to resistance is an area of interest and I have led clinical trials of HGF/MET inhibitors combined with VEGF-targeted therapies.


Board Certifications

1981
Internal Medicine, Board Certified
1983
Medical Oncology, Board Certified
1984
Hematology (Internal Medicine), Board Certified

Patient Care Locations

joseph_ederfaculty-clinicsfalsetruetrue6truefalsefalse

Clinical Trials

ConditionsStudy Title
Colorectal Cancer and ColonC80702: A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer
Bladder, Breast - Female, Colon, Lung, Melanoma, skin, Other Endocrine System, Other Respiratory and Intrathoracic Organs, Other Urinary, Ovary, Rectum, and StomachA Phase I, open-label, multiple ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications
Bladder, Breast - Female, Breast - Male, Colon, Kidney, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Other Skin, Other Urinary, Pancreas, Prostate, Small Intestine, and StomachA Phase 1, Multicenter, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KTN3379 in Adult Subjects with Advanced Tumors
Bladder, Breast - Female, Lung, Pancreas, and StomachA Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
Breast - Female, Colon, Esophagus, Kidney, Liver, Lung, Melanoma, skin, and PancreasA Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With Advanced Solid Tumors

More Clinical Trials...

Edit Profile